FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3208346081> ?p ?o ?g. }

• W3208346081 endingPage "1279" @default.
• W3208346081 startingPage "1265" @default.
• W3208346081 abstract "Abstract Background Our understanding of coronavirus disease 2019 (COVID-19) and its implications for patients with inflammatory bowel diseases (IBD) is rapidly evolving. We performed a systematic review and meta-analysis to investigate the epidemiology, clinical characteristics, and outcomes in IBD patients with COVID-19. Methods We searched PubMed, EMBASE, Cochrane Central, Clinicaltrials.gov, Web of Science, MedRxiv, and Google Scholar from inception through October 2020. We included studies with IBD patients and confirmed COVID-19. Data were collected on the prevalence, patient characteristics, pre-infection treatments for IBD, comorbidities, hospitalization, intensive care unit (ICU), admission, and death. Results Twenty-three studies with 51,643 IBD patients and 1449 with COVID-19 met our inclusion criteria. In 14 studies (n = 50,706) that included IBD patients with and without COVID-19, the prevalence of infection was 1.01% (95% confidence interval [CI], 0.92-1.10). Of IBD patients with COVID-19, 52.7% had Crohn’s disease, 42.2% had ulcerative colitis, and 5.1% had indeterminate colitis. Nine studies (n = 687) reported outcomes according to IBD therapy received. Compared with patients on corticosteroids, those on antitumor necrosis factor (anti-TNF) therapy had a lower risk of hospitalization (risk ratio [RR], 0.24; 95% CI, 0.16-0.35; P &lt; .01; I2 = 0%) and ICU admission (RR, 0.10; 95% CI, 0.03-0.37; P &lt; .01) but not death (RR, 0.16; 95% CI, 0.02-1.71; P = .13; I2 = 39%). Compared with patients on mesalamine, those on antitumor necrosis factor therapy had a lower risk of hospitalizations (RR, 0.37; 95% CI, 0.25-0.54), ICU admissions (RR, 0.20; 95% CI, 0.07-0.58), and death (0.21; 95% CI, 0.04-1.00). Comparing patients on immunomodulators vs mesalamine or anti-TNF therapy, there was no difference in these outcomes. Conclusions The prevalence of COVID-19 in IBD patients was low. Use of corticosteroids or mesalamine was significantly associated with worse outcomes, whereas use of anti-TNFs was associated with more favorable outcomes. Further investigation clarifying the mechanisms of these disparate observations could help identify risk and adverse outcome-mitigating strategies for patients with IBD." @default.
• W3208346081 created "2021-11-08" @default.
• W3208346081 creator A5044290840 @default.
• W3208346081 creator A5064393418 @default.
• W3208346081 creator A5065597646 @default.
• W3208346081 creator A5075665344 @default.
• W3208346081 creator A5085014241 @default.
• W3208346081 creator A5085731324 @default.
• W3208346081 creator A5086915192 @default.
• W3208346081 creator A5088914633 @default.
• W3208346081 date "2021-10-27" @default.
• W3208346081 modified "2023-10-12" @default.
• W3208346081 title "COVID-19 and Outcomes in Patients With Inflammatory Bowel Disease: Systematic Review and Meta-Analysis" @default.
• W3208346081 cites W2062237052 @default.
• W3208346081 cites W2936769587 @default.
• W3208346081 cites W3001118548 @default.
• W3208346081 cites W3001897055 @default.
• W3208346081 cites W3005544777 @default.
• W3208346081 cites W3014673464 @default.
• W3208346081 cites W3014851567 @default.
• W3208346081 cites W3015861468 @default.
• W3208346081 cites W3016274830 @default.
• W3208346081 cites W3016434872 @default.
• W3208346081 cites W3018029174 @default.
• W3208346081 cites W3019058772 @default.
• W3208346081 cites W3019322791 @default.
• W3208346081 cites W3021062080 @default.
• W3208346081 cites W3021115216 @default.
• W3208346081 cites W3022587459 @default.
• W3208346081 cites W3022795287 @default.
• W3208346081 cites W3022998208 @default.
• W3208346081 cites W3023428589 @default.
• W3208346081 cites W3024177957 @default.
• W3208346081 cites W3025301240 @default.
• W3208346081 cites W3030927265 @default.
• W3208346081 cites W3031587586 @default.
• W3208346081 cites W3032592392 @default.
• W3208346081 cites W3033336208 @default.
• W3208346081 cites W3033531806 @default.
• W3208346081 cites W3033733785 @default.
• W3208346081 cites W3035110973 @default.
• W3208346081 cites W3035881525 @default.
• W3208346081 cites W3036445432 @default.
• W3208346081 cites W3036453504 @default.
• W3208346081 cites W3036809604 @default.
• W3208346081 cites W3038373202 @default.
• W3208346081 cites W3039741445 @default.
• W3208346081 cites W3044841741 @default.
• W3208346081 cites W3046477310 @default.
• W3208346081 cites W3048781969 @default.
• W3208346081 cites W3075807079 @default.
• W3208346081 cites W3080429955 @default.
• W3208346081 cites W3080825697 @default.
• W3208346081 cites W3081137866 @default.
• W3208346081 cites W3081486763 @default.
• W3208346081 cites W3082229420 @default.
• W3208346081 cites W3082473930 @default.
• W3208346081 cites W3087033936 @default.
• W3208346081 cites W3092330732 @default.
• W3208346081 cites W3093754216 @default.
• W3208346081 cites W3094105410 @default.
• W3208346081 cites W3094406031 @default.
• W3208346081 cites W3101694102 @default.
• W3208346081 cites W3165656738 @default.
• W3208346081 doi "https://doi.org/10.1093/ibd/izab236" @default.
• W3208346081 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8574492" @default.
• W3208346081 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34718595" @default.
• W3208346081 hasPublicationYear "2021" @default.
• W3208346081 type Work @default.
• W3208346081 sameAs 3208346081 @default.
• W3208346081 citedByCount "29" @default.
• W3208346081 countsByYear W32083460812021 @default.
• W3208346081 countsByYear W32083460812022 @default.
• W3208346081 countsByYear W32083460812023 @default.
• W3208346081 crossrefType "journal-article" @default.
• W3208346081 hasAuthorship W3208346081A5044290840 @default.
• W3208346081 hasAuthorship W3208346081A5064393418 @default.
• W3208346081 hasAuthorship W3208346081A5065597646 @default.
• W3208346081 hasAuthorship W3208346081A5075665344 @default.
• W3208346081 hasAuthorship W3208346081A5085014241 @default.
• W3208346081 hasAuthorship W3208346081A5085731324 @default.
• W3208346081 hasAuthorship W3208346081A5086915192 @default.
• W3208346081 hasAuthorship W3208346081A5088914633 @default.
• W3208346081 hasBestOaLocation W32083460811 @default.
• W3208346081 hasConcept C107130276 @default.
• W3208346081 hasConcept C126322002 @default.
• W3208346081 hasConcept C2776376669 @default.
• W3208346081 hasConcept C2778260677 @default.
• W3208346081 hasConcept C2779134260 @default.
• W3208346081 hasConcept C2779280984 @default.
• W3208346081 hasConcept C2780479503 @default.
• W3208346081 hasConcept C44249647 @default.
• W3208346081 hasConcept C71924100 @default.
• W3208346081 hasConcept C82789193 @default.
• W3208346081 hasConcept C90924648 @default.
• W3208346081 hasConcept C95190672 @default.
• W3208346081 hasConceptScore W3208346081C107130276 @default.
• W3208346081 hasConceptScore W3208346081C126322002 @default.

• next